The latter is an alternative promoter variant of the ERα, encoded by the ESR1 gene, which has been associated with poor prognosis of mammary cancers and resistance to oestrogen therapies (Thiebaut et al., 2020). This evidence concerns the gene ESR1 and breast cancer.